{"result": {"id": "62b1c91c-1431-4828-934d-f0b23477912e", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>SPS3 STUDY GROUP<|>ORGANIZATION<|>A research group that studied blood-pressure targets in patients with recent lacunar stroke)\n##\n(\"entity\"<|>FEVER STUDY<|>ORGANIZATION<|>A study investigating the benefits of early blood pressure control on cardiovascular outcomes)\n##\n(\"entity\"<|>SMASH PROJECT<|>ORGANIZATION<|>A project studying urinary sodium/potassium excretion and blood pressure in adults)\n##\n(\"entity\"<|>ASCOT TRIAL<|>ORGANIZATION<|>A trial studying legacy benefits of blood pressure treatment on cardiovascular events)\n##\n(\"entity\"<|>SHANDONG PROVINCE<|>GEO<|>Chinese province where the SMASH project studied blood pressure factors)\n##\n(\"relationship\"<|>SPS3 STUDY GROUP<|>BENAVENTE OR<|>Benavente OR is a researcher involved in the SPS3 Study Group<|>8)\n##\n(\"relationship\"<|>SPS3 STUDY GROUP<|>COFFEY CS<|>Coffey CS is a researcher involved in the SPS3 Study Group<|>8)\n##\n(\"relationship\"<|>FEVER STUDY<|>ZHANG Y<|>Zhang Y is a researcher involved in the FEVER Study<|>8)\n##\n(\"relationship\"<|>FEVER STUDY<|>ZHANG X<|>Zhang X is a researcher involved in the FEVER Study<|>8)\n##\n(\"relationship\"<|>FEVER STUDY<|>LIU L<|>Liu L is a researcher involved in the FEVER Study<|>8)\n##\n(\"relationship\"<|>SMASH PROJECT<|>CHEN X<|>Chen X is a researcher involved in the SMASH project<|>8)\n##\n(\"relationship\"<|>SMASH PROJECT<|>GUO X<|>Guo X is a researcher involved in the SMASH project<|>8)\n##\n(\"relationship\"<|>SMASH PROJECT<|>MA J<|>Ma J is a researcher involved in the SMASH project<|>8)\n##\n(\"relationship\"<|>ASCOT TRIAL<|>GUPTA A<|>Gupta A is a researcher involved in the ASCOT trial<|>8)\n##\n(\"relationship\"<|>ASCOT TRIAL<|>WHITELEY WN<|>Whiteley WN is a researcher involved in the ASCOT trial<|>8)\n##\n(\"relationship\"<|>ASCOT TRIAL<|>GODEC T<|>Godec T is a researcher involved in the ASCOT trial<|>8)\n##\n(\"relationship\"<|>SMASH PROJECT<|>SHANDONG PROVINCE<|>The SMASH project was conducted in Shandong Province<|>7)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558979, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 628, "prompt_tokens": 5893, "total_tokens": 6521, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 5824}, "prompt_cache_hit_tokens": 5824, "prompt_cache_miss_tokens": 69}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 967.\n[136]  Brunstr?m M, CarlbergB.  Associationofbloodpressurelower- ing with mortality and cardiovasculardisease across blood pres- surelevels: asystematicreview andmeta-analysis[J]. JAMA In- tern Med,2018,178(1) :28-36.\n[137]  LonnEM, BoschJ, López-JaramilloP, etal. Blood-pressurelower- ing in intermediate-risk persons without cardiovascular disease [J]. N EnglJ Med,2016,374(21) :2009-2020.\n[138]  刘靖.  高血压治疗 :基于血压水平 ,还是基于风险?  [J]. 中华高 血压杂志 ,2017,25(2) :108-110.\n[139]  ACCORD StudyGroup, CushmanWC, EvansGW, etal. Effects ofintensive blood-pressure control in type 2 diabetes mellitus [J]. N EnglJ Med,2010,362(17) :1575-1585.\n[140]  SPS3 Study Group,  Benavente OR, Coffey CS, et al.  Blood- pressuretargetsinpatientswithrecentlacunarstroke: theSPS3 randomised trial[J]. Lancet,2013,382(9891) :507-515.\n[141]  SPRINT ResearchGroup, WrightJT, Jr, WilliamsonJD, etal.   A randomized trial of intensive versus standard blood-pressure control[J]. N EnglJ Med,2015,373(22) :2103-2116.\n[142]  Zhang W ,  Zhang S, Deng Y, et al.  Trial of intensive blood-\n\n\n　pressurecontrolinolderpatientswithhypertension[J]. NEnglJ Med,2021,385(14) :1268-1279.\n[143]  BangaloreS, Toklu B, GianosE, etal.  Optimalsystolicblood pressuretarget after SPRINT: insights from a network meta- analysisofrandomized trials[J]. Am J Med, 2017, 130(6) : 707- 719. e8.\n[144]  Whelton PK, CareyRM, Aronow WS, etal. 2017ACC/AHA/ AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guide- lineforthe prevention, detection, evaluation, and management ofhighblood pressure in adults: a reportofthe American Col- lege of Cardiology/American Heart Association task force on clinicalpractice guidelines[J]. Hypertension, 2018, 71(6) : e13- e115.\n[145]  StergiouG, Brunstr?m M, MacDonaldT, etal.  Bedtimedosing ofantihypertensive medications: systematic review and consen- sus statement:  International Society of Hypertension position paper endorsed by World Hypertension League and European SocietyofHypertension[J]. J Hypertens, 2022, 40(10) : 1847- 1858.\n[146]  SchutteAE, Jafar TH, PoulterNR, et al.  Addressing global disparitiesinbloodpressurecontrol: perspectivesoftheInterna- tionalSociety of Hypertension[J]. Cardiovasc Res, 2023, 119\n(2) :381-409.\n[147]  ParatiG, TorlascoC, PengoM, etal. Blood pressurevariabili- ty: itsrelevanceforcardiovascularhomeostasisand cardiovascu- lardiseases[J]. HypertensRes,2020,43(7) :609-620.\n[148]  Gupta A, Whiteley WN, Godec T,  et al.  Legacy benefits of blood pressure treatmenton cardiovascular events are primarily mediated by improved blood pressure variability:  the ASCOT  trial[J]. EurHeartJ,2024,45(13) :1159-1169.\n[149]  DoumasM, Tsioufis C, FletcherR, etal. Time in therapeutic range, as a determinant of all-cause mortality in patients with hypertension[J]. JAm HeartAssoc,2017,6(11) :e007131.\n[150]  ChungSC, Pujades-RodriguezM, DuyxB, etal. Timespentat blood pressure target and the risk of death and cardiovascular diseases[J]. PLoSOne,2018,13(9) :e0202359.\n[151]  ZhangY, Zhang X, Liu L, etal.  Benefits ofearlyblood pres- surecontrolon cardiovascularoutcomes: a subgroup analysis of theFelodipineEventReduction(FEVER) Study[J]. J Clin Hy- pertens,2016,34:e36.\n[152]  Martín-FernándezM, VinyolesE, RealJ, etal. Theprognostic valueofblood pressure controldelay in newly diagnosed hyper- tensivepatients[J]. J Hypertens,2019,37(2) :426-431.\n[153]  Chen X, Guo X, MaJ, etal. Urinary sodium orpotassium ex- cretion and blood pressure in adults of Shandong province,  China: preliminary resultsoftheSMASH project[J]. JAm Soc Hypertens,2015,9(10) :754-762.\n[154]  Sacks FM, Svet\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>ACCORD STUDY GROUP<|>ORGANIZATION<|>A research group that studied the effects of intensive blood-pressure control in type 2 diabetes mellitus)\n##\n(\"entity\"<|>SPRINT RESEARCH GROUP<|>ORGANIZATION<|>A research group that conducted a randomized trial of intensive versus standard blood-pressure control)\n##\n(\"entity\"<|>INTERNATIONAL SOCIETY OF HYPERTENSION<|>ORGANIZATION<|>An organization addressing global disparities in blood pressure control and providing consensus statements on hypertension management)\n##\n(\"entity\"<|>AMERICAN COLLEGE OF CARDIOLOGY<|>ORGANIZATION<|>An organization involved in setting guidelines for the prevention, detection, evaluation, and management of high blood pressure in adults)\n##\n(\"entity\"<|>AMERICAN HEART ASSOCIATION<|>ORGANIZATION<|>An organization involved in setting guidelines for the prevention, detection, evaluation, and management of high blood pressure in adults)\n##\n(\"entity\"<|>WORLD HYPERTENSION LEAGUE<|>ORGANIZATION<|>An organization endorsing position papers on hypertension management)\n##\n(\"entity\"<|>EUROPEAN SOCIETY OF HYPERTENSION<|>ORGANIZATION<|>An organization endorsing position papers on hypertension management)\n##\n(\"entity\"<|>BRUNSTRÖM M<|>PERSON<|>Researcher associated with studies on blood pressure lowering and its association with mortality and cardiovascular disease)\n##\n(\"entity\"<|>CARLBERG B<|>PERSON<|>Researcher associated with studies on blood pressure lowering and its association with mortality and cardiovascular disease)\n##\n(\"entity\"<|>LONN EM<|>PERSON<|>Researcher involved in studies on blood-pressure lowering in intermediate-risk persons without cardiovascular disease)\n##\n(\"entity\"<|>BOSCH J<|>PERSON<|>Researcher involved in studies on blood-pressure lowering in intermediate-risk persons without cardiovascular disease)\n##\n(\"entity\"<|>LÓPEZ-JARAMILLO P<|>PERSON<|>Researcher involved in studies on blood-pressure lowering in intermediate-risk persons without cardiovascular disease)\n##\n(\"entity\"<|>CUSHMAN WC<|>PERSON<|>Researcher involved in the ACCORD Study Group, studying effects of intensive blood-pressure control in type 2 diabetes mellitus)\n##\n(\"entity\"<|>EVANS GW<|>PERSON<|>Researcher involved in the ACCORD Study Group, studying effects of intensive blood-pressure control in type 2 diabetes mellitus)\n##\n(\"entity\"<|>BENAVENTE OR<|>PERSON<|>Researcher involved in the SPS3 Study Group, studying blood-pressure targets in patients with recent lacunar stroke)\n##\n(\"entity\"<|>COFFEY CS<|>PERSON<|>Researcher involved in the SPS3 Study Group, studying blood-pressure targets in patients with recent lacunar stroke)\n##\n(\"entity\"<|>WRIGHT JT<|>PERSON<|>Researcher involved in the SPRINT Research Group, conducting a randomized trial of intensive versus standard blood-pressure control)\n##\n(\"entity\"<|>WILLIAMSON JD<|>PERSON<|>Researcher involved in the SPRINT Research Group, conducting a randomized trial of intensive versus standard blood-pressure control)\n##\n(\"entity\"<|>ZHANG W<|>PERSON<|>Researcher involved in a trial of intensive blood-pressure control in older patients with hypertension)\n##\n(\"entity\"<|>ZHANG S<|>PERSON<|>Researcher involved in a trial of intensive blood-pressure control in older patients with hypertension)\n##\n(\"entity\"<|>DENG Y<|>PERSON<|>Researcher involved in a trial of intensive blood-pressure control in older patients with hypertension)\n##\n(\"entity\"<|>BANGALORE S<|>PERSON<|>Researcher involved in studies on optimal systolic blood pressure targets after SPRINT)\n##\n(\"entity\"<|>TOKLU B<|>PERSON<|>Researcher involved in studies on optimal systolic blood pressure targets after SPRINT)\n##\n(\"entity\"<|>GIANOS E<|>PERSON<|>Researcher involved in studies on optimal systolic blood pressure targets after SPRINT)\n##\n(\"entity\"<|>WHELTON PK<|>PERSON<|>Researcher involved in setting guidelines for the prevention, detection, evaluation, and management of high blood pressure in adults)\n##\n(\"entity\"<|>CAREY RM<|>PERSON<|>Researcher involved in setting guidelines for the prevention, detection, evaluation, and management of high blood pressure in adults)\n##\n(\"entity\"<|>ARONOW WS<|>PERSON<|>Researcher involved in setting guidelines for the prevention, detection, evaluation, and management of high blood pressure in adults)\n##\n(\"entity\"<|>STERGIOU G<|>PERSON<|>Researcher involved in studies on bedtime dosing of antihypertensive medications)\n##\n(\"entity\"<|>MACDONALD T<|>PERSON<|>Researcher involved in studies on bedtime dosing of antihypertensive medications)\n##\n(\"entity\"<|>SCHUTTE AE<|>PERSON<|>Researcher involved in addressing global disparities in blood pressure control)\n##\n(\"entity\"<|>JAFAR TH<|>PERSON<|>Researcher involved in addressing global disparities in blood pressure control)\n##\n(\"entity\"<|>POULTER NR<|>PERSON<|>Researcher involved in addressing global disparities in blood pressure control)\n##\n(\"entity\"<|>PARATI G<|>PERSON<|>Researcher involved in studies on blood pressure variability and its relevance for cardiovascular homeostasis and diseases)\n##\n(\"entity\"<|>TORLASCO C<|>PERSON<|>Researcher involved in studies on blood pressure variability and its relevance for cardiovascular homeostasis and diseases)\n##\n(\"entity\"<|>PENGO M<|>PERSON<|>Researcher involved in studies on blood pressure variability and its relevance for cardiovascular homeostasis and diseases)\n##\n(\"entity\"<|>GUPTA A<|>PERSON<|>Researcher involved in studies on the legacy benefits of blood pressure treatment on cardiovascular events)\n##\n(\"entity\"<|>WHITELEY WN<|>PERSON<|>Researcher involved in studies on the legacy benefits of blood pressure treatment on cardiovascular events)\n##\n(\"entity\"<|>GODEC T<|>PERSON<|>Researcher involved in studies on the legacy benefits of blood pressure treatment on cardiovascular events)\n##\n(\"entity\"<|>DOUMAS M<|>PERSON<|>Researcher involved in studies on time in therapeutic range as a determinant of all-cause mortality in patients with hypertension)\n##\n(\"entity\"<|>TSIOUFIS C<|>PERSON<|>Researcher involved in studies on time in therapeutic range as a determinant of all-cause mortality in patients with hypertension)\n##\n(\"entity\"<|>FLETCHER R<|>PERSON<|>Researcher involved in studies on time in therapeutic range as a determinant of all-cause mortality in patients with hypertension)\n##\n(\"entity\"<|>CHUNG SC<|>PERSON<|>Researcher involved in studies on time spent at blood pressure target and the risk of death and cardiovascular diseases)\n##\n(\"entity\"<|>PUJADES-RODRIGUEZ M<|>PERSON<|>Researcher involved in studies on time spent at blood pressure target and the risk of death and cardiovascular diseases)\n##\n(\"entity\"<|>DUYX B<|>PERSON<|>Researcher involved in studies on time spent at blood pressure target and the risk of death and cardiovascular diseases)\n##\n(\"entity\"<|>ZHANG Y<|>PERSON<|>Researcher involved in studies on the benefits of early blood pressure control on cardiovascular outcomes)\n##\n(\"entity\"<|>ZHANG X<|>PERSON<|>Researcher involved in studies on the benefits of early blood pressure control on cardiovascular outcomes)\n##\n(\"entity\"<|>LIU L<|>PERSON<|>Researcher involved in studies on the benefits of early blood pressure control on cardiovascular outcomes)\n##\n(\"entity\"<|>MARTÍN-FERNÁNDEZ M<|>PERSON<|>Researcher involved in studies on the prognostic value of blood pressure control delay in newly diagnosed hypertensive patients)\n##\n(\"entity\"<|>VINYOLES E<|>PERSON<|>Researcher involved in studies on the prognostic value of blood pressure control delay in newly diagnosed hypertensive patients)\n##\n(\"entity\"<|>REAL J<|>PERSON<|>Researcher involved in studies on the prognostic value of blood pressure control delay in newly diagnosed hypertensive patients)\n##\n(\"entity\"<|>CHEN X<|>PERSON<|>Researcher involved in studies on urinary sodium or potassium excretion and blood pressure in adults)\n##\n(\"entity\"<|>GUO X<|>PERSON<|>Researcher involved in studies on urinary sodium or potassium excretion and blood pressure in adults)\n##\n(\"entity\"<|>MA J<|>PERSON<|>Researcher involved in studies on urinary sodium or potassium excretion and blood pressure in adults)\n##\n(\"entity\"<|>SACKS FM<|>PERSON<|>Researcher involved in studies on dietary approaches to stop hypertension)\n##\n(\"entity\"<|>SVETKEY LP<|>PERSON<|>Researcher involved in studies on dietary approaches to stop hypertension)\n##\n(\"relationship\"<|>ACCORD STUDY GROUP<|>CUSHMAN WC<|>Cushman WC is a researcher involved in the ACCORD Study Group<|>8)\n##\n(\"relationship\"<|>ACCORD STUDY GROUP<|>EVANS GW<|>Evans GW is a researcher involved in the ACCORD Study Group<|>8)\n##\n(\"relationship\"<|>SPRINT RESEARCH GROUP<|>WRIGHT JT<|>Wright JT is a researcher involved in the SPRINT Research Group<|>8)\n##\n(\"relationship\"<|>SPRINT RESEARCH GROUP<|>WILLIAMSON JD<|>Williamson JD is a researcher involved in the SPRINT Research Group<|>8)\n##\n(\"relationship\"<|>INTERNATIONAL SOCIETY OF HYPERTENSION<|>SCHUTTE AE<|>Schutte AE is a researcher involved in the International Society of Hypertension<|>8)\n##\n(\"relationship\"<|>INTERNATIONAL SOCIETY OF HYPERTENSION<|>JAFAR TH<|>Jafar TH is a researcher involved in the International Society of Hypertension<|>8)\n##\n(\"relationship\"<|>INTERNATIONAL SOCIETY OF HYPERTENSION<|>POULTER NR<|>Poulter NR is a researcher involved in the International Society of Hypertension<|>8)\n##\n(\"relationship\"<|>AMERICAN COLLEGE OF CARDIOLOGY<|>WHELTON PK<|>Whelton PK is a researcher involved in the American College of Cardiology<|>8)\n##\n(\"relationship\"<|>AMERICAN COLLEGE OF CARDIOLOGY<|>CAREY RM<|>Carey RM is a researcher involved in the American College of Cardiology<|>8)\n##\n(\"relationship\"<|>AMERICAN COLLEGE OF CARDIOLOGY<|>ARONOW WS<|>Aronow WS is a researcher involved in the American College of Cardiology<|>8)\n##\n(\"relationship\"<|>AMERICAN HEART ASSOCIATION<|>WHELTON PK<|>Whelton PK is a researcher involved in the American Heart Association<|>8)\n##\n(\"relationship\"<|>AMERICAN HEART ASSOCIATION<|>CAREY RM<|>Carey RM is a researcher involved in the American Heart Association<|>8)\n##\n(\"relationship\"<|>AMERICAN HEART ASSOCIATION<|>ARONOW WS<|>Aronow WS is a researcher involved in the American Heart Association<|>8)\n##\n(\"relationship\"<|>WORLD HYPERTENSION LEAGUE<|>STERGIOU G<|>Stergiou G is a researcher involved in the World Hypertension League<|>8)\n##\n(\"relationship\"<|>EUROPEAN SOCIETY OF HYPERTENSION<|>STERGIOU G<|>Stergiou G is a researcher involved in the European Society of Hypertension<|>8)\n##\n(\"relationship\"<|>INTERNATIONAL SOCIETY OF HYPERTENSION<|>WORLD HYPERTENSION LEAGUE<|>The International Society of Hypertension and the World Hypertension League collaborate on hypertension management<|>6)\n##\n(\"relationship\"<|>INTERNATIONAL SOCIETY OF HYPERTENSION<|>EUROPEAN SOCIETY OF HYPERTENSION<|>The International Society of Hypertension and the European Society of Hypertension collaborate on hypertension management<|>6)\n##\n(\"relationship\"<|>AMERICAN COLLEGE OF CARDIOLOGY<|>AMERICAN HEART ASSOCIATION<|>The American College of Cardiology and the American Heart Association collaborate on setting guidelines for hypertension management<|>7)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_b9ec553d5105dd436d0883383ec08c161bdc47b2982c977d9bd079c2de67cdf0_v2"}